Manufacturing and Supply, page-24

Hi TGA 

Like all statistics the devil is I the detail.

The RAS trial was carried out in the Serenje District of Zambia, and controlled by members of Transaid, MMV and partners. All suspected cases (I presume all children) were treated with RAS and referred to health facilities where 1066 patients were treated. It is great that the results were more or less the same as the trials that were carried with ArTiMist(90 to 94% cure)…..not at all surprised by thisstatistic as the products are the same, the real point of difference is in the application. OM spray V a Suppository.....I know what  my preference would be as either a patient or giving pre-referral treatment.

However according to the World Malaria Report 2017 there were 5M more malaria cases in 2016 than in 2015 and malaria deaths stood at 445000, a similar number to the previous year.

The Director General of WHO stated that without urgent action we risk going backwards and missing global targets for 2020 and beyond. The WHO Global Technical Strategy calls for reductions of at least 40% in malaria case incidence and mortality rates by 2020 and the world is not on track to reach these critical milestones. (2020 is very, very close)

Seeing the greatest mortality is in the pediatric cohort, surely that is where the focus should be instead of all the dithering that WHO seem to do  as they bend over backwards to appease their financial sponsors at the expense of saving children's lives.

Hopefully some progress in the first quarter of 2019

Happy Christmas Everyone

kippax